CJC-1295 with DAC
Product Overview
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been modified to extend its half-life significantly. The addition of the DAC component allows for sustained release and prolonged biological activity compared to native GHRH.
Molecular Specifications
- Molecular Formula: C165H271N47O46
- Molecular Weight: 3647.28 Da
- Sequence Length: 30 amino acids + DAC modification
- Purity: ≥98% (HPLC verified)
- Appearance: White lyophilized powder
- Solubility: Soluble in sterile water and bacteriostatic water
Structural Modifications
The DAC (Drug Affinity Complex) modification involves the covalent attachment of a reactive chemical group that binds to circulating albumin in vivo. This albumin binding significantly extends the peptide's half-life from minutes to days, allowing for less frequent dosing in research protocols.
Research Applications
This compound is utilised in various research contexts investigating:
- Growth hormone releasing hormone receptor signaling
- Pituitary gland function and hormone regulation
- Growth hormone secretion patterns and kinetics
- Metabolic regulation and energy homeostasis
- Age-related hormonal changes and interventions
- Pharmacokinetic studies of modified peptides
Storage & Handling
- Storage Temperature: -20°C (lyophilised), 2-8°C (reconstituted, short-term)
- Stability: 24 months lyophilised, 30 days reconstituted at 2-8°C
- Reconstitution: Use sterile water or bacteriostatic water
- Half-life: Extended (6-8 days) due to DAC modification
Quality Assurance
Each batch undergoes comprehensive analytical testing including HPLC purity analysis, mass spectrometry verification, amino acid analysis, and endotoxin testing. Certificate of Analysis provided with each shipment.
For research purposes only. Not for human consumption or therapeutic use.
